Screened 2026-09-09 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
GE HealthCare holds its Markdown at $65.17. The statistical read favours the buyers, held for 18 days.
As held on the ledger · 2026-09-09
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 18 days
Price at the screen
$65.17
Valuation
15.02 trailing · 12.05 forward price to earnings
Values screen
PASS· score 82.8
Beta
0.82
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
28.35%
Below 33%
Interest-bearing debt is just 28.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.95%
Below 33%
Cash held in interest-bearing accounts and securities is 1.0% of assets, under the one-third limit.
Pass
Receivables
22.25%
Below 49%
Money owed to the company is 22.2% of assets, under the 49% limit.
Pass
Revenue purity
0.20%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 47% discount to our $96.00 fair value, narrow competitive moat, 5.80% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. A 47.3% margin of safety to the base estimate.
Third-party analyst targets: 18 covering, consensus Buy. The average target sits +27% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Hospitals rely on kit that rarely fails
Walk into any busy imaging suite and the scanners and monitors keeping patients safe often trace back to established medical device makers. GE HealthCare stands out here because it combines 7% revenue growth, a 19% return on equity and a forward earnings multiple of just 11.8 times, all while clearing the ethical screen and offering a 55% margin of safety to our fair value.
The narrow moat and 9% profit margin reflect steady but not explosive demand for diagnostic and monitoring gear worldwide. Eighteen analysts see further upside with a median target of 80 dollars, yet the real attraction is the cash generation and pricing power that still sits below what the market normally awards similar healthcare compounders.
Risk sits mainly in hospital capital budgets that can tighten quickly during funding squeezes, plus competition that keeps the moat from widening. Currency moves and supply chain hiccups add further volatility. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GEHC trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 22.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80.
2026-07-31Distribution$61.12-5.5%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 5.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80.
2026-07-18Distribution$64.67+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it buy, with a mean price target of $80.
2026-07-03Distribution$64.67+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$64.67Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
